Interestingly, the remestemcel-L doses were given 48 hours apart in these two cases, representing a slightly shorter time interval than what has been previously utilized for steroid- resistant graft-versus-host disease. Although this alternative dosing schedule was unplanned, the concept of a “rapid sequence” of doses may actually be beneficial in MIS-C given its very rapid disease progression and hyperacute inflammatory state. The shorter interval between doses appeared safe and efficacious in our two children and should be considered in the design of future trials for MIS-C and other acute inflammatory conditions.
Still learning sweetspots .
Brightened my day.
Bodes well for Covid Ards.
Reg.
Tickity Toc
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-26
-
- There are more pages in this discussion • 398 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.030(3.13%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 96.5¢ | $1.03 | 96.5¢ | $4.704M | 4.708M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 87395 | 98.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 274051 | 2 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |